Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect of Ammoxetine Hydrochloride in Healthy Participants
NCT07756996Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ammoxetine in major depressive disorder (MDD) (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Plasma Maximum concentration up to 60 hours and Area under the concentration-time curve up to 60 hours. Started Jul 2026; status: recruiting.
02
Drugs
ammoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07756996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756996.